Published in Blood on February 24, 2010
Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol (2014) 2.12
Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release (2013) 1.64
Glycogene expression alterations associated with pancreatic cancer epithelial-mesenchymal transition in complementary model systems. PLoS One (2010) 1.34
Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol Ther (2012) 1.29
CD169 mediates the capture of exosomes in spleen and lymph node. Blood (2013) 1.20
Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis. J Clin Invest (2013) 1.19
Sialoadhesin promotes rapid proinflammatory and type I IFN responses to a sialylated pathogen, Campylobacter jejuni. J Immunol (2012) 1.14
Siglecs as sensors of self in innate and adaptive immune responses. Ann N Y Acad Sci (2012) 1.08
Sialoadhesin in recognition of self and non-self. Semin Immunopathol (2012) 1.05
Immunoconjugates and long circulating systems: origins, current state of the art and future directions. Adv Drug Deliv Rev (2012) 1.05
Antigen delivery to macrophages using liposomal nanoparticles targeting sialoadhesin/CD169. PLoS One (2012) 1.04
Glycotherapy: new advances inspire a reemergence of glycans in medicine. Chem Biol (2013) 1.04
CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells. J Immunol (2010) 1.04
Coiled-coil based drug-free macromolecular therapeutics: in vivo efficacy. J Control Release (2011) 1.00
Targeted delivery of lipid antigen to macrophages via the CD169/sialoadhesin endocytic pathway induces robust invariant natural killer T cell activation. Proc Natl Acad Sci U S A (2013) 0.97
Copresentation of antigen and ligands of Siglec-G induces B cell tolerance independent of CD22. J Immunol (2013) 0.96
Cell surface self-assembly of hybrid nanoconjugates via oligonucleotide hybridization induces apoptosis. ACS Nano (2013) 0.93
Developmental, malignancy-related, and cross-species analysis of eosinophil, mast cell, and basophil siglec-8 expression. J Clin Immunol (2011) 0.92
Click and pick: identification of sialoside analogues for siglec-based cell targeting. Angew Chem Int Ed Engl (2012) 0.92
Dexamethasone-loaded block copolymer nanoparticles induce leukemia cell death and enhance therapeutic efficacy: a novel application in pediatric nanomedicine. Mol Pharm (2012) 0.91
In silico-aided design of a glycan ligand of sialoadhesin for in vivo targeting of macrophages. J Am Chem Soc (2012) 0.90
A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab. Theranostics (2015) 0.86
Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches. Trends Pharmacol Sci (2015) 0.84
Disubstituted Sialic Acid Ligands Targeting Siglecs CD33 and CD22 Associated with Myeloid Leukaemias and B Cell Lymphomas. Chem Sci (2014) 0.84
Multivalent ligands for siglecs. Methods Enzymol (2010) 0.83
CD22-antagonists with nanomolar potency: the synergistic effect of hydrophobic groups at C-2 and C-9 of sialic acid scaffold. Bioorg Med Chem (2011) 0.82
Glycan-targeted virus-like nanoparticles for photodynamic therapy. Biomacromolecules (2012) 0.81
Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22. Leuk Lymphoma (2011) 0.81
Oligomannose-coated liposome as a novel adjuvant for the induction of cellular immune responses to control disease status. Biomed Res Int (2013) 0.80
Development of antimetastatic drugs by targeting tumor sialic acids. Sci Pharm (2012) 0.80
Targeted delivery of mycobacterial antigens to human dendritic cells via Siglec-7 induces robust T cell activation. J Immunol (2014) 0.79
The detection and discovery of glycan motifs in biological samples using lectins and antibodies: new methods and opportunities. Adv Cancer Res (2015) 0.79
On-chip synthesis and screening of a sialoside library yields a high affinity ligand for Siglec-7. ACS Chem Biol (2013) 0.79
Preferences for uptake of carbohydrate-coated liposomes by C-type lectin receptors as antigen-uptake receptors. Glycoconj J (2012) 0.78
Visualizing Trimming Dependence of Biodistribution and Kinetics with Homo- and Heterogeneous N-Glycoclusters on Fluorescent Albumin. Sci Rep (2016) 0.78
Hitting the sweet spot for lymphoma. Blood (2010) 0.77
Sequential Double "Clicks" toward Structurally Well-Defined Heterogeneous N-Glycoclusters: The Importance of Cluster Heterogeneity on Pattern Recognition In Vivo. Adv Sci (Weinh) (2016) 0.77
Lipidoid nanoparticle mediated silencing of Mcl-1 induces apoptosis in mantle cell lymphoma. Exp Biol Med (Maywood) (2016) 0.77
Targeting brain cells with glutathione-modulated nanoliposomes: in vitro and in vivo study. Drug Des Devel Ther (2015) 0.76
Controlled Multi-functionalization Facilitates Targeted Delivery of Nanoparticles to Cancer Cells. Chemistry (2015) 0.75
Turning-Off Signaling by Siglecs, Selectins, and Galectins: Chemical Inhibition of Glycan-Dependent Interactions in Cancer. Front Oncol (2016) 0.75
In vitro and in vivo effects of free and chalcones-loaded nanoemulsions: insights and challenges in targeted cancer chemotherapies. Int J Environ Res Public Health (2014) 0.75
Structural characterisation of high affinity Siglec-2 (CD22) ligands in complex with whole Burkitt's lymphoma (BL) Daudi cells by NMR spectroscopy. Sci Rep (2016) 0.75
Liposomes modified by carbohydrate ligands can target B cells for the treatment of B-cell lymphomas. Expert Rev Vaccines (2010) 0.75
Cell surface and in vivo interaction of dendrimeric N-glycoclusters. Glycoconj J (2015) 0.75
Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov (2005) 10.97
Siglecs and their roles in the immune system. Nat Rev Immunol (2007) 7.98
Influencing receptor-ligand binding mechanisms with multivalent ligand architecture. J Am Chem Soc (2002) 2.94
Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta (1993) 2.92
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med (2001) 2.65
Nanoparticle-based targeted drug delivery. Exp Mol Pathol (2009) 2.62
A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med (2008) 2.44
Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations. Blood (2001) 2.25
"In vivo" depletion of macrophages by liposome-mediated "suicide". Methods Enzymol (2003) 2.17
Cell surface biology mediated by low affinity multivalent protein-glycan interactions. Curr Opin Chem Biol (2004) 2.05
Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol Sci (2009) 2.04
Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity. Mol Cell Biol (2007) 1.84
Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res (2008) 1.71
High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells. J Immunol (2006) 1.65
Sialoadhesin expressed on IFN-induced monocytes binds HIV-1 and enhances infectivity. PLoS One (2008) 1.59
CD22: an inhibitory enigma. Immunology (2007) 1.43
Sialoside analogue arrays for rapid identification of high affinity siglec ligands. J Am Chem Soc (2008) 1.42
Non-Hodgkin lymphoma. Lancet (2003) 1.40
CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo. J Immunol (2006) 1.37
Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact. Proc Natl Acad Sci U S A (2004) 1.35
Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. Clin Cancer Res (2000) 1.33
Structure-guided design of sialic acid-based Siglec inhibitors and crystallographic analysis in complex with sialoadhesin. Structure (2003) 1.32
Sialoadhesin-deficient mice exhibit subtle changes in B- and T-cell populations and reduced immunoglobulin M levels. Mol Cell Biol (2006) 1.29
Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood (1993) 1.29
Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia (2007) 1.21
Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin. Clin Lymphoma Myeloma (2008) 1.17
Targeted drugs and nanomedicine: present and future. Curr Pharm Des (2009) 1.17
Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. J Control Release (2007) 1.14
Pegylated liposomal doxorubicin in ovarian cancer. Int J Nanomedicine (2006) 1.13
Newer monoclonal antibodies for hematological malignancies. Exp Hematol (2008) 1.13
A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS One (2009) 1.10
Bifunctional CD22 ligands use multimeric immunoglobulins as protein scaffolds in assembly of immune complexes on B cells. J Am Chem Soc (2008) 1.09
A carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle. Cancer Res (2006) 1.04
Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. Blood (2001) 1.04
Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice. Int J Cancer (1990) 1.01
Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program (2007) 1.00
Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors. Mol Cancer Ther (2006) 0.99
Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res (2006) 0.99
Recent developments in carbohydrate-decorated targeted drug/gene delivery. Med Res Rev (2010) 0.90
Polymerized liposome assemblies: bifunctional macromolecular selectin inhibitors mimicking physiological selectin ligands. Biochemistry (2001) 0.90
Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells. Cancer Lett (2008) 0.88
Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma. Med Oncol (2002) 0.88
Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma. Anticancer Res (2002) 0.88
Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail. Blood (1994) 0.87
High-efficacy site-directed drug delivery system using sialyl-Lewis X conjugated liposome. Exp Eye Res (2007) 0.85
Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B-Cell chronic lymphoproliferative disorders from admixed benign B cells in four-color multiparameter flow cytometry. Am J Clin Pathol (2005) 0.85
Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science (2006) 10.04
Siglecs and their roles in the immune system. Nat Rev Immunol (2007) 7.98
Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci U S A (2004) 7.55
Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J Mol Biol (2005) 6.17
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science (2011) 5.44
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science (2008) 4.11
New world bats harbor diverse influenza A viruses. PLoS Pathog (2013) 4.10
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood (2002) 4.00
Characterization of H7N9 influenza A viruses isolated from humans. Nature (2013) 3.71
Contemporary North American influenza H7 viruses possess human receptor specificity: Implications for virus transmissibility. Proc Natl Acad Sci U S A (2008) 3.45
In vitro evolution of H5N1 avian influenza virus toward human-type receptor specificity. Virology (2011) 3.19
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol (2013) 3.11
Recent avian H5N1 viruses exhibit increased propensity for acquiring human receptor specificity. J Mol Biol (2008) 3.00
Replication and transmission of H9N2 influenza viruses in ferrets: evaluation of pandemic potential. PLoS One (2008) 2.86
Glycan microarray technologies: tools to survey host specificity of influenza viruses. Nat Rev Microbiol (2006) 2.83
Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog (2013) 2.66
A general strategy for the chemoenzymatic synthesis of asymmetrically branched N-glycans. Science (2013) 2.49
High-efficiency labeling of sialylated glycoproteins on living cells. Nat Methods (2009) 2.46
The murine inhibitory receptor mSiglec-E is expressed broadly on cells of the innate immune system whereas mSiglec-F is restricted to eosinophils. Eur J Immunol (2004) 2.38
Effect of receptor binding domain mutations on receptor binding and transmissibility of avian influenza H5N1 viruses. Virology (2011) 2.28
Evidence for ozone formation in human atherosclerotic arteries. Science (2003) 2.22
Homomultimeric complexes of CD22 in B cells revealed by protein-glycan cross-linking. Nat Chem Biol (2005) 2.22
Frontiers in glycomics: bioinformatics and biomarkers in disease. An NIH white paper prepared from discussions by the focus groups at a workshop on the NIH campus, Bethesda MD (September 11-13, 2006). Proteomics (2008) 2.09
Glycomics: an integrated systems approach to structure-function relationships of glycans. Nat Methods (2005) 2.06
Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6'-sulfo-sialyl Lewis X as a preferred glycan ligand. Glycobiology (2005) 2.06
Cell surface biology mediated by low affinity multivalent protein-glycan interactions. Curr Opin Chem Biol (2004) 2.05
Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol Sci (2009) 2.04
Synthesis of sugar arrays in microtiter plate. J Am Chem Soc (2002) 1.96
Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci U S A (2003) 1.91
Recognition of sialylated meningococcal lipopolysaccharide by siglecs expressed on myeloid cells leads to enhanced bacterial uptake. Mol Microbiol (2003) 1.87
Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity. Mol Cell Biol (2007) 1.84
Glycan microarrays for decoding the glycome. Annu Rev Biochem (2011) 1.81
Functional balance of the hemagglutinin and neuraminidase activities accompanies the emergence of the 2009 H1N1 influenza pandemic. J Virol (2012) 1.76
Characterization of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursors. Blood (2006) 1.76
Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome. Nat Chem Biol (2012) 1.70
Sialoside specificity of the siglec family assessed using novel multivalent probes: identification of potent inhibitors of myelin-associated glycoprotein. J Biol Chem (2003) 1.68
High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells. J Immunol (2006) 1.65
Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. Blood (2013) 1.64
Structural characterization of the hemagglutinin receptor specificity from the 2009 H1N1 influenza pandemic. J Virol (2011) 1.62
A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin. Nat Struct Mol Biol (2013) 1.60
Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9. J Biol Chem (2004) 1.60
Structure, receptor binding, and antigenicity of influenza virus hemagglutinins from the 1957 H2N2 pandemic. J Virol (2009) 1.50
Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol (2003) 1.50
A focused microarray approach to functional glycomics: transcriptional regulation of the glycome. Glycobiology (2005) 1.49
Siglec-G is a B1 cell-inhibitory receptor that controls expansion and calcium signaling of the B1 cell population. Nat Immunol (2007) 1.48
Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo. J Exp Med (2009) 1.44
Hemagglutinin homologue from H17N10 bat influenza virus exhibits divergent receptor-binding and pH-dependent fusion activities. Proc Natl Acad Sci U S A (2013) 1.44
Neoglycolipid probes prepared via oxime ligation for microarray analysis of oligosaccharide-protein interactions. Chem Biol (2007) 1.42
Sialoside analogue arrays for rapid identification of high affinity siglec ligands. J Am Chem Soc (2008) 1.42
Covalent display of oligosaccharide arrays in microtiter plates. J Am Chem Soc (2004) 1.40
Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation? Immunology (2010) 1.37
Preferential recognition of avian-like receptors in human influenza A H7N9 viruses. Science (2013) 1.37
Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact. Proc Natl Acad Sci U S A (2004) 1.35
Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and -independent mechanisms. Eur J Immunol (2003) 1.35
Crystal structures of two subtype N10 neuraminidase-like proteins from bat influenza A viruses reveal a diverged putative active site. Proc Natl Acad Sci U S A (2012) 1.34
Dendritic cell maturation results in pronounced changes in glycan expression affecting recognition by siglecs and galectins. J Immunol (2007) 1.34
Activation of murine CD4+ and CD8+ T lymphocytes leads to dramatic remodeling of N-linked glycans. J Immunol (2006) 1.34
Sialic acid-binding immunoglobulin-like lectin 7 mediates selective recognition of sialylated glycans expressed on Campylobacter jejuni lipooligosaccharides. Infect Immun (2006) 1.34
Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J Allergy Clin Immunol (2007) 1.32
Structure-guided design of sialic acid-based Siglec inhibitors and crystallographic analysis in complex with sialoadhesin. Structure (2003) 1.32
Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling. Nat Immunol (2005) 1.31
Receptor specificity of subtype H1 influenza A viruses isolated from swine and humans in the United States. Virology (2011) 1.31
Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer (2010) 1.30
Sialoadhesin-deficient mice exhibit subtle changes in B- and T-cell populations and reduced immunoglobulin M levels. Mol Cell Biol (2006) 1.29
Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol Ther (2012) 1.29
Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci U S A (2006) 1.28
On-virus construction of polyvalent glycan ligands for cell-surface receptors. J Am Chem Soc (2008) 1.26
Influenza virus neuraminidases with reduced enzymatic activity that avidly bind sialic Acid receptors. J Virol (2012) 1.25
Recognition of sialylated poly-N-acetyllactosamine chains on N- and O-linked glycans by human and avian influenza A virus hemagglutinins. Angew Chem Int Ed Engl (2012) 1.23
Siglec-E is up-regulated and phosphorylated following lipopolysaccharide stimulation in order to limit TLR-driven cytokine production. J Immunol (2009) 1.23
A small region of the natural killer cell receptor, Siglec-7, is responsible for its preferred binding to alpha 2,8-disialyl and branched alpha 2,6-sialyl residues. A comparison with Siglec-9. J Biol Chem (2001) 1.22
Individual plasmacytoid dendritic cells are major contributors to the production of multiple innate cytokines in an organ-specific manner during viral infection. Int Immunol (2007) 1.22
The M/GP(5) glycoprotein complex of porcine reproductive and respiratory syndrome virus binds the sialoadhesin receptor in a sialic acid-dependent manner. PLoS Pathog (2010) 1.22
Combinatorial antibody libraries from cancer patients yield ligand-mimetic Arg-Gly-Asp-containing immunoglobulins that inhibit breast cancer metastasis. Proc Natl Acad Sci U S A (2004) 1.21
Receptor specificity of influenza A H3N2 viruses isolated in mammalian cells and embryonated chicken eggs. J Virol (2010) 1.21
Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. Chem Biol (2010) 1.21
CD169 mediates the capture of exosomes in spleen and lymph node. Blood (2013) 1.20
Cloning and characterization of human Siglec-11. A recently evolved signaling molecule that can interact with SHP-1 and SHP-2 and is expressed by tissue macrophages, including brain microglia. J Biol Chem (2002) 1.20
Sialoadhesin promotes the inflammatory response in experimental autoimmune uveoretinitis. J Immunol (2006) 1.20
Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis. J Clin Invest (2013) 1.19
SOCS3 targets Siglec 7 for proteasomal degradation and blocks Siglec 7-mediated responses. J Biol Chem (2006) 1.16
Expression of CD33-related siglecs on human mononuclear phagocytes, monocyte-derived dendritic cells and plasmacytoid dendritic cells. Immunobiology (2004) 1.16
Sialoadhesin-positive macrophages bind regulatory T cells, negatively controlling their expansion and autoimmune disease progression. J Immunol (2009) 1.16
Siglec-5 (CD170) can mediate inhibitory signaling in the absence of immunoreceptor tyrosine-based inhibitory motif phosphorylation. J Biol Chem (2005) 1.16
Alpha2,6-sialic acid on platelet endothelial cell adhesion molecule (PECAM) regulates its homophilic interactions and downstream antiapoptotic signaling. J Biol Chem (2010) 1.16
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med (2015) 1.15
MIRAGE: the minimum information required for a glycomics experiment. Glycobiology (2014) 1.14
Sialoadhesin promotes rapid proinflammatory and type I IFN responses to a sialylated pathogen, Campylobacter jejuni. J Immunol (2012) 1.14
Siglec-E is a negative regulator of acute pulmonary neutrophil inflammation and suppresses CD11b β2-integrin-dependent signaling. Blood (2013) 1.13
Characterization of the specific interaction between sialoadhesin and sialylated Campylobacter jejuni lipooligosaccharides. Infect Immun (2010) 1.13
High resolution crystal structures of Siglec-7. Insights into ligand specificity in the Siglec family. J Biol Chem (2002) 1.12
Eosinophil-selective binding and proapoptotic effect in vitro of a synthetic Siglec-8 ligand, polymeric 6'-sulfated sialyl Lewis x. J Pharmacol Exp Ther (2009) 1.12
Human Siglec-10 can bind to vascular adhesion protein-1 and serves as its substrate. Blood (2009) 1.10
Siglec-7 undergoes a major conformational change when complexed with the alpha(2,8)-disialylganglioside GT1b. J Biol Chem (2006) 1.09